🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨WATCH THIS NOW. Van Jones is saying what needs to be said. Jews are being firebombed in America. And the response from the so-called “progressive” crowd? 👉 “But what about Gaza?” No one’s attacking Russian-Americans over Ukraine. No one’s attacking Ukrainian-Americans

Something's coming... 🫁 +🎙️#staytuned Follow @oncnewscentral and @lunccancerrx for the exciting launch this week! Eric K. Singhi, MD @fawziaburous @adesaimd Jill Feldman EGFR Resisters #lungcancer #NSCLC #SCLC #ASCO25

18 years ago today, Hamas staged a military coup and violently took over Gaza. But to understand how it got to that point, we need to go back a little bit. Gaza was a part of the Ottoman Empire for centuries, and later, the British mandate, and in 1948, was under Egyptian

The first two episodes of the LungCancerRx 🫁💊 podcast will be released this Friday, June 13th! Recording the first two episodes live with Eric K. Singhi, MD Fawzi Abu Rous, MD & Aakash Desai, MD, MPH, FASCO was incredible - one of the most real, honest and fun conversations I've had! These are the conversations

Officially launched!!! LungCancerRx 🫁💊 - a podcast prescribing what truly matters: Empowerment Knowledge & Hope oncologynewscentral.com/video/lung-can… Jill Feldman Eric K. Singhi, MD Aakash Desai, MD, MPH, FASCO Fawzi Abu Rous, MD Oncology News Central

The LungCancerRx 🫁💊 podcast is live! 🎧 We talked about empowerment, the importance of communication, and the lived experience - not just the diagnosis, but the impact, decisions, scanxiety, etc. I've told my story many times in many settings. This was different because my family

We are SO excited to be back for #TumorBoardTuesday!! Will you join us? EGFR Resisters Jill Feldman Bruna Pellini, MD Aakash Desai, MD, MPH, FASCO Fawzi Abu Rous, MD Oncology Brothers Ana I. Velázquez Mañana, MD, MSc, FASCO Arthi Sridhar

#TumorBoardTuesday Eric K. Singhi, MD Integrity CE, LLC 2/20 #TumorBoardTuesday   🩻 Staging PET: b/l multifocal 🫁 lesions, mediastinal LAD  🧠 MRI: 1 cm single brain met Pt w/ no neuro sx

#TumorBoardTuesday Eric K. Singhi, MD Integrity CE, LLC 3/20 #TumorBoardTuesday Given updated data since our last case, which systemic tx would you offer NOW? 🧐

#TumorBoardTuesday Eric K. Singhi, MD Integrity CE, LLC 4/20 #TumorBoardTuesday   👨🏽‍🏫Mini Tweetorial 1👨🏽‍🏫 💊 Per NCCN, choices A-C are all reasonable category 1 1L recommendations for CLASSICAL EGFR (ex19del or L858R) mutations  🧐 Let’s delve into the updates since our last #TBT to guide our decision making!

Important to remember that patients can only benefit if they are able to tolerate it and The #COCOON data shows that proactive management of side effects reduces them and increases #QOL That Matters! #TumorBoardTuesday #LCSM

#TumorBoardTuesday Eric K. Singhi, MD Integrity CE, LLC 7/20 #TumorBoardTuesday 👨🏽‍🏫Mini Tweetorial 4👨🏽‍🏫 🧠 What about the CNS?  ✅ CNS PFS 24.9 mo (vs. Osi 22.2 mo) ✅ 3-year CNS PFS 36% vs. 18% w/ Osi

#TumorBoardTuesday Eric K. Singhi, MD Integrity CE, LLC 8/20 #TumorBoardTuesday 👨🏽‍🏫Mini Tweetorial 5👨🏽‍🏫 Which subgroups particularly benefit from Ami/Laz vs. Osi monotherapy❓ 🧠Brain mets 🍸Liver mets 🧬TP53 co-mutation 🩸+baseline EGFRm ctDNA ⛔️no EGFRm ctDNA clearance

Key info here about CNS efficacy from #MARIPOSA for our patients 🧠 Recall that serial brain MRIs were mandated on the study! Kelsey Pan, MD, MPH #TumorBoardTuesday

Jill Feldman Interesting point, Jill. The emphasis on managing side effects proactively is crucial for improving patient outcomes and Quality of Life (#QOL). It would be fascinating to delve into how these approaches can be standardized across different treatments. What are some of the

This is a beautiful illustration by Julia Rotow MD But from discussions in our community, sequencing in routine clinic is more of an art than science. This emphasizes the importance of there is no one size fits all treatment approach - the right first line depends on preferences

SKIPPirr Study gilberto lopes et al. 👇🏽👇🏽

Great summary by Kelsey Pan, MD, MPH of tonight’s #TumorBoardTuesday discussion on the evolving frontline landscape for EGFR+ NSCLC—the meme doesn’t hurt 🤣 Oncology Brothers LungCancerRx 🫁💊 EGFR Resisters Jill Feldman

THIS ⬇️ Patients don’t experience side effects separately from survival, impact & #QOL. #TumorBoardTuesday #LCSM

When Israel strikes terrorists hiding in hospitals after warning and evacuating civilians, the world cries war crime. When Iran bombs an Israeli hospital full of civilians—justification. “We need verification!” “We need context!” “They deserved it!” “Maybe there was a military